利用Primer Explorer V4在线软件设计针对B亚型禽偏肺病毒(aMPV)F基因的特异性引物,并从反应时间、温度、各组分浓度等方面优化了反应体系和反应条件,建立了B亚型aMPV逆转录环介导等温核酸扩增(RT-LAMP)快速检测方法。该方法能够在63℃...利用Primer Explorer V4在线软件设计针对B亚型禽偏肺病毒(aMPV)F基因的特异性引物,并从反应时间、温度、各组分浓度等方面优化了反应体系和反应条件,建立了B亚型aMPV逆转录环介导等温核酸扩增(RT-LAMP)快速检测方法。该方法能够在63℃条件下1h内实现B亚型aMPV F基因片段的特异性扩增,与其他病毒,如H9N2亚型禽流感病毒(AIV)、新城疫病毒(NDV)、传染性支气管炎病毒(IBV)、传染性法氏囊病病毒(IBDV)等的核酸无交叉反应。反应结果可直接用肉眼判断。对质粒DNA的最小检测量为1×102拷贝/μL。利用建立的检测方法对20份疑似aMPV样品进行检测,其阳性检出率为10%。结果表明,建立的B亚型aMPV RT-LAMP检测方法具有快速、准确、特异性强、灵敏度高的特点,可应用于相关疾病的临床诊断。展开更多
Avian metapneumovirus (aMPV) and Newcastle disease virus (NDV) are threatening avian pathogens that can cause serious respiratory diseases in poultry worldwide. Vaccination, combined with strict biosecurity practices,...Avian metapneumovirus (aMPV) and Newcastle disease virus (NDV) are threatening avian pathogens that can cause serious respiratory diseases in poultry worldwide. Vaccination, combined with strict biosecurity practices, has been the recommendation for controlling these diseases in the field. In the present study, we generated NDV LaSota vaccine strain-based recombinant viruses expressing the glycoprotein (G) of aMPV, subtype A or B, using reverse genetics technology. These recombinant viruses, rLS/aMPV-A G and rLS/aMPV-B G, were characterized in cell cultures and evaluated in turkeys as bivalent, next-generation vaccines. The results showed that these recombinant vaccine candi-dates were slightly attenuated in vivo, yet maintained similar growth dynamics, cytopathic effects, and virus titers in vitro when compared to the parental LaSota virus. The expression of the aMPV G protein in recombinant virus-infected cells was detected by immunofluorescence. Vaccination of turkeys with rLS/aMPV-A G or rLS/aMPV-B G conferred complete protection against velogenic NDV, CA02 strain challenge and partial protection against homologous patho-genic aMPV challenge. These results suggest that the LaSota recombinant virus is a safe and effective vaccine vector and expression of the G protein alone is not sufficient to provide full protection against aMPV-A or -B infections. Ex-pression of other aMPV-A or -B virus immunogenic protein(s) individually or in conjunction with the G protein may be necessary to induce stronger and more protective immunity against aMPV diseases.展开更多
文摘利用Primer Explorer V4在线软件设计针对B亚型禽偏肺病毒(aMPV)F基因的特异性引物,并从反应时间、温度、各组分浓度等方面优化了反应体系和反应条件,建立了B亚型aMPV逆转录环介导等温核酸扩增(RT-LAMP)快速检测方法。该方法能够在63℃条件下1h内实现B亚型aMPV F基因片段的特异性扩增,与其他病毒,如H9N2亚型禽流感病毒(AIV)、新城疫病毒(NDV)、传染性支气管炎病毒(IBV)、传染性法氏囊病病毒(IBDV)等的核酸无交叉反应。反应结果可直接用肉眼判断。对质粒DNA的最小检测量为1×102拷贝/μL。利用建立的检测方法对20份疑似aMPV样品进行检测,其阳性检出率为10%。结果表明,建立的B亚型aMPV RT-LAMP检测方法具有快速、准确、特异性强、灵敏度高的特点,可应用于相关疾病的临床诊断。
文摘Avian metapneumovirus (aMPV) and Newcastle disease virus (NDV) are threatening avian pathogens that can cause serious respiratory diseases in poultry worldwide. Vaccination, combined with strict biosecurity practices, has been the recommendation for controlling these diseases in the field. In the present study, we generated NDV LaSota vaccine strain-based recombinant viruses expressing the glycoprotein (G) of aMPV, subtype A or B, using reverse genetics technology. These recombinant viruses, rLS/aMPV-A G and rLS/aMPV-B G, were characterized in cell cultures and evaluated in turkeys as bivalent, next-generation vaccines. The results showed that these recombinant vaccine candi-dates were slightly attenuated in vivo, yet maintained similar growth dynamics, cytopathic effects, and virus titers in vitro when compared to the parental LaSota virus. The expression of the aMPV G protein in recombinant virus-infected cells was detected by immunofluorescence. Vaccination of turkeys with rLS/aMPV-A G or rLS/aMPV-B G conferred complete protection against velogenic NDV, CA02 strain challenge and partial protection against homologous patho-genic aMPV challenge. These results suggest that the LaSota recombinant virus is a safe and effective vaccine vector and expression of the G protein alone is not sufficient to provide full protection against aMPV-A or -B infections. Ex-pression of other aMPV-A or -B virus immunogenic protein(s) individually or in conjunction with the G protein may be necessary to induce stronger and more protective immunity against aMPV diseases.
